High BMI at Start of Advanced RCC Systemic Therapy Ups Survival Odds
In a study of patients starting first-line systemic therapy for advanced renal cell carcinoma, patients with a low BMI were twice as likely to die as those with a high BMI.
Patients with a higher body mass index (BMI) at the start of systemic treatment for advanced renal cell carcinoma (RCC) have a greater likelihood of survival, according to investigators.
The findings is from an analysis of data from 606 patients with advanced RCC in a prospective German cohort who were initiating systemic first-line treatment. Peter J. Goebell, MD, of University Hospital Erlangen in Erlangen, Germany, and colleagues stratified patients into low (148 patients), medium (251 patients), and high BMI (207 patients) groups (less than 24, 24–28, and more than 28 kg/m2, respectively). The median overall survival in these groups was 10.9, 17.9, and 24.5, months, respectively, the investigators reported online ahead of print in Urologic Oncology.
Compared with a high BMI, a low BMI was associated with a significant 2-fold greater risk of death, and a medium BMI was associated with a significant 1.4-fold greater risk of death, independent of known predictors such as Memorial Sloan Kettering Cancer Center score, according to Dr Goebell and his colleagues.
Women made up 29.7% of the study population, which had a mean age of 68.2 years. The mean BMI in the low, medium, and high BMI groups was 21.7, 25.9, and 32 kg/m2, respectively.
Goebell PJ, Muller L, Hubner A, et al. Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment—Analyses from the German clinical RCC-Registry. Urol Oncol. 2018; published online ahead of print.